$55.80
2.174.05%
Last update: Nov 10, 8:56 AM
Genmab AS
GMABNASDAQ
Genmab AS rose 92.0% from $29.06 to $55.80, ahead of the S&P 500's +10.5%. Its worst day was Mar 3 (−6.7%), and its low came Jun 2 at $23.85.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.05 missed the $0.44 estimate on $1.1B revenue (est. $4.4B); FY revenue guidance of $4.1B–$4.4B against the $4.4B consensus.
−0.1% · S&P 500 +0.2%
EPS of $0.08 missed the $0.17 estimate on $896.0M revenue (est. $4.7B); FY revenue guidance of $4.1B–$4.4B against the $22.9B consensus.
Story events cover the past 12 months · Times ET
−3.0% · S&P 500 −0.3%
Genmab AS closed at its lowest level of the year, 17.9% below where the year started.
−6.3% · S&P 500 +0.1%
EPS of $4.91 beat the $0.31 estimate on $1.2B revenue (est. $5.8B); FY revenue guidance of $4.3B–$4.5B against the $4.4B consensus.
+1.9% · S&P 500 −0.2%
Treatment with Rina-S 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer
+10.7% · S&P 500 +0.7%
Genmab AS closed at its highest level of the year, 97.1% above where the year started.
+28.3%, the year's best day, on 29M shares, the year's heaviest volume · S&P 500 +0.3%
EPS of $5.51 beat the $0.33 estimate on $1.2B revenue (est. $6.7B); FY revenue guidance of $4.3B–$4.5B against the $4.5B consensus.
−4.3% · S&P 500 −4.4%
Where it ended: a close of $55.80 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 16, 2027 (EPS est. $0.19, revenue est. $7.0B).
Nothing in the past 12 months.
All GMAB dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GMAB and SPY from Benzinga historical bars. Not investment advice.
